By Colin Kellaher
Nurix Therapeutics has won a key U.S. Food and Drug Administration designation for its lead asset bexobrutideg in a rare type of non-Hodgkin's lymphoma.
Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma characterized by the replacement of normal bone marrow cells by malignant lymphocytic cells.
The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. It also provides for an extended marketing exclusivity period against competition.
Nurix, a San Francisco clinical-stage biopharmaceutical company, is evaluating bexobrutideg in a Phase 1 study in patients with relapsed or refractory B cell malignancies.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2025 07:59 ET (11:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.